What the FDA labels say about taking them together
Cyclosporine and tocilizumab
Tocilizumab's FDA label of December 16, 2025 names cyclosporine in its drug interactions section; the cyclosporine labels PlainMeds reads (4) do not name tocilizumab. The tocilizumab label: “Upon initiation or discontinuation of TYENNE, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration and the individual dose of …”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the tocilizumab FDA label on DailyMed (effective December 16, 2025, Genentech, Inc.).
What does the cyclosporine label say about tocilizumab?
Cyclosporine's label (effective August 10, 2026) and its 3 other brand-application labels do not name tocilizumab in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the tocilizumab label say about cyclosporine?
Tocilizumab label, drug interactionsUpon initiation or discontinuation of ACTEMRA, in patients being treated with these types of medicinal products, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) and the individual dose of the medicinal product adjusted as needed.
Source: FDA drug label (Avtozma, BLA761420), CELLTRION USA, Inc., effective July 27, 2026 (SPL set 581c288f-8015-40ef-a4c3-683c96db193d), via openFDA
Source: FDA drug label (Tyenne, BLA761275), Fresenius Kabi USA, LLC, effective August 26, 2026 (SPL set ad76441d-da59-47df-8d9d-2243005180f0), via openFDA
Source: FDA drug label (ACTEMRA), Genentech, Inc., effective December 16, 2025 (SPL set 2e5365ff-cb2a-4b16-b2c7-e35c6bf2de13), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Tocilizumab | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | Rheumatoid arthritis, COVID-19 |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $821.00 per mL 162 mg/0.9 mL autoinjct |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once